The European Medicines Agency (EMA) is taking steps to enhance clinical trial transparency, following a recent analysis that found less than half of registered studies were reported within the required time frame.[5280784] This move comes after an investigation found weak compliance with legal reporting requirements and inadequate regulatory oversight in the European Union and European Economic Area.[5280784] The analysis, which examined the Clinical Trial Information System (CTIS), found that only 42% of complete results were fully reported, highlighting a need for greater transparency in clinical trials.[5280784] Regulatory bodies are convening experts to discuss standards for clinical artificial intelligence, with the goal of establishing a consensus set of principles.[5259971] The White House and the Department of Health and Human Services will convene experts in a one-month sprint to develop benchmarking and evaluation guidelines for clinical AI.[5259971]